Oral News and Research

RSS

FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

Silvergate Pharmaceuticals, Inc., focused on the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration approved Epaned for the treatment of symptomatic heart failure and the treatment of asymptomatic left ventricular dysfunction (to decrease the rate of development of overt heart failure and to reduce hospitalization for heart failure).

9 Sep 2014

Canada funds 22 inventive ideas for improving health in low-resource countries

Grand Challenges Canada, funded by the Government of Canada, today announced $2.4 million in seed funds shared between 22 projects from Canada and nine developing nations, to pursue inventive new ideas for improving health in low-resource countries.

8 Sep 2014

New antifungal drug effective against invasive mold disease in cancer patients with less adverse effects

A newly developed antifungal, isavuconazole, is as effective as an existing drug, voriconazole, against invasive mold disease in cancer patients with less adverse effects, according to phase 3 clinical data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, an infectious disease meeting of the American Society for Microbiology.

8 Sep 2014

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the acquisition of a novel orphan drug candidate, known as SGX301 (synthetic hypericin).

8 Sep 2014

Peramivir drug safe, effective at alleviating influenza symptoms

An analysis of phase 2 and phase 3 clinical trials shows that a single injected dose of the neuraminidase inhibitor (NAI) peramivir is safe and effective at alleviating influenza symptoms, including fever and viral shedding, when administered within 48 hours of the onset of symptoms.

6 Sep 2014

FDA provides QIDP designation to Debiopharm’s Debio 1450 for treatment of ABSSSI

Debiopharm Group™(Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs including anti-infective and oncology therapeutics as well as companion diagnostics, today announced that the US Food and Drug Administration (FDA) has designated its anti-infectious agent Debio 1450 as a Qualified Infectious Disease Product (QIDP) for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

4 Sep 2014

OSAP hosts 2015 Boot Camp for dental practitioners

Today the Organization for Safety, Asepsis and Prevention (OSAP) announced that they will host the 2015 Boot Camp: Infection Control Basic Training in Atlanta, Ga. from Jan. 12-14, 2015.

4 Sep 2014

Positive clinical data for first procedural therapy to treat type 2 diabetes from Fractyl

Fractyl Laboratories Inc. today announced positive clinical data for the first procedural therapy to directly treat the underlying digestive causes of insulin resistance in patients with uncontrolled type 2 diabetes.

4 Sep 2014

Bristol-Myers Squibb launches Daklinza in the UK for treatment of chronic hepatitis C

Bristol-Myers Squibb today announced the launch of Daklinza▼ (daclatasvir) in the UK, a new medicine for the treatment of adult patients with chronic hepatitis C. Daclatasvir, a treatment that works across multiple hepatitis C genotypes, will allow up to 90% of UK patients the option of a potentially curative oral treatment regimen that does not include interferon, a standard of care commonly associated with sustained flu-like side effects.

4 Sep 2014

F2G begins F901318 Phase I clinical study for treatment of aspergillus infections

F2G Limited, the antifungal research and development company today announced a major milestone in the development of its novel IV/ oral systemic antifungal (F901318) with the commencement of a Phase I clinical study.

4 Sep 2014

Treatment with SSRIs linked with increased failure risk of osseointegrated implants

The International and American Associations for Dental Research (IADR/AADR) have published a paper titled "SSRIs and the Risk of Osseointegrated Implant Failure - A Cohort Study.

4 Sep 2014

Infinity and AbbVie enter into global collaboration to develop and commercialize duvelisib

Infinity Pharmaceuticals, Inc. and AbbVie Inc. today announced that they have entered into a global collaboration to develop and commercialize duvelisib (IPI-145), Infinity's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of patients with cancer.

3 Sep 2014

Synthetic announces positive results from final preclinical toxicology study of SYN-004

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today positive results from its final preclinical toxicology study of SYN-004.

2 Sep 2014

Kids, adolescents are at increased risk of developing diabetes if exposed to antipsychotics

A study published in the September 2014 issue of the Journal of the American Academy of Child and Adolescent Psychiatry found that children and adolescents diagnosed with a psychiatric diagnosis had an increased risk of developing diabetes if they were exposed to antipsychotics.

2 Sep 2014

New polypill increases adherence to treatment following myocardial infarction

A new polypill increases adherence to treatment following a myocardial infarction (MI), according to results from the FOCUS Study presented for the first time at ESC Congress 2014 today by principal investigator Dr Valentin Fuster, director of Mount Sinai Heart in New York, US.

1 Sep 2014

Morbidity, mortality of AF patients remains high at 1 year even with good use of oral anticoagulants

Mortality and morbidity of atrial fibrillation (AF) patients remains high at one year despite good use of oral anticoagulants, according to the one year follow up of the Atrial Fibrillation General Pilot Registry.

1 Sep 2014

Wockhardt receives coveted QIDP status from FDA for WCK 771 and WCK 2349 drugs

Wockhardt Limited today announces a major boost to the New Drug Discovery program in Anti-Infective research when two of its drugs, WCK 771 and WCK 2349, received the coveted Qualified Infectious Disease Product (QIDP) status from U.S. Food & Drug Administration.

1 Sep 2014

Oral News and Research

FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

Canada funds 22 inventive ideas for improving health in low-resource countries

New antifungal drug effective against invasive mold disease in cancer patients with less adverse effects

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Peramivir drug safe, effective at alleviating influenza symptoms

FDA provides QIDP designation to Debiopharm’s Debio 1450 for treatment of ABSSSI

OSAP hosts 2015 Boot Camp for dental practitioners

Positive clinical data for first procedural therapy to treat type 2 diabetes from Fractyl

Bristol-Myers Squibb launches Daklinza in the UK for treatment of chronic hepatitis C

F2G begins F901318 Phase I clinical study for treatment of aspergillus infections

Treatment with SSRIs linked with increased failure risk of osseointegrated implants

Infinity and AbbVie enter into global collaboration to develop and commercialize duvelisib

Synthetic announces positive results from final preclinical toxicology study of SYN-004

Kids, adolescents are at increased risk of developing diabetes if exposed to antipsychotics

New polypill increases adherence to treatment following myocardial infarction

Morbidity, mortality of AF patients remains high at 1 year even with good use of oral anticoagulants

Wockhardt receives coveted QIDP status from FDA for WCK 771 and WCK 2349 drugs

ESC launches first recommendations on use of all new oral anticoagulants in pulmonary embolism

FASEB MARC Program announces recipients of travel award

Semi-soft vaginal suppository provides drug-delivery vehicle to prevent spread of HIV

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News